[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545106":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":288,"collaborators":290,"id":293,"slug":294,"hasResults":295,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":10,"eligibilityCriteria":298,"healthyVolunteers":295,"sex":299,"minAge":300,"maxAge":10,"enrollmentInfo":301,"targetDuration":304,"studyType":305,"phases":10,"briefSummary":306,"conditions":307,"keywords":10,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":318},{"fullName":5,"class":6},"French Innovative Leukemia Organisation","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"AML in 1st line at inclusion",null,{"label":12,"type":10,"description":10,"interventionNames":10},"AML in R\u002FR at inclusion",[14],{"name":15,"affiliation":5,"role":16},"Pierre PETERLIN, Dr","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Ariane MINEUR","CONTACT","+33 (0)5 57 62 31 08","ariane.mineur@chu-bordeaux.fr",[24,40,52,64,76,89,101,115,127,139,151,163,175,187,202,214,226,240,252,264,276],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Amiens CHU","NOT_YET_RECRUITING","Amiens","France","FR",{"type":31,"coordinates":32},"Point",[33,34],2.3,49.9,{"lat":34,"lon":33},[37],{"name":38,"role":20,"phone":10,"phoneExt":10,"email":39},"Delphine Lebon, Dr","lebon.delphine@chu-amiens.fr",{"facility":41,"status":26,"city":42,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Angers CHU","Angers",{"type":31,"coordinates":44},[45,46],-0.55202,47.47156,{"lat":46,"lon":45},[49],{"name":50,"role":20,"phone":10,"phoneExt":10,"email":51},"corentin Orvain, Dr","corentin.orvain@chu-angers.fr",{"facility":53,"status":26,"city":54,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Bayonne CH","Bayonne",{"type":31,"coordinates":56},[57,58],-1.473,43.49316,{"lat":58,"lon":57},[61],{"name":62,"role":20,"phone":10,"phoneExt":10,"email":63},"Anne Banos, Dr","abanos@ch-cotebasque.fr",{"facility":65,"status":26,"city":66,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Besançon CHU","Besançon",{"type":31,"coordinates":68},[69,70],6.01815,47.24878,{"lat":70,"lon":69},[73],{"name":74,"role":20,"phone":10,"phoneExt":10,"email":75},"Yohann Desbrosses, Dr","ydesbrosses@chu-besancon.fr",{"facility":77,"status":78,"city":79,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU Estaing","RECRUITING","Clermont-Ferrand",{"type":31,"coordinates":81},[82,83],3.08682,45.77969,{"lat":83,"lon":82},[86],{"name":87,"role":20,"phone":10,"phoneExt":10,"email":88},"Gaspar Aspas Requena, MD","gaspasrequena@chu-clermontferrand.fr",{"facility":90,"status":78,"city":91,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Créteil CHU HENRI MONDOR","Créteil",{"type":31,"coordinates":93},[94,95],2.46569,48.79266,{"lat":95,"lon":94},[98],{"name":99,"role":20,"phone":10,"phoneExt":10,"email":100},"Cécile Pautas, Dr","cecile.pautas@aphp.fr",{"facility":102,"status":78,"city":103,"state":10,"zip":104,"country":28,"countryCode":29,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"DUNKERQUE-Hôpital Alexandra Lepève","Dunkirk","59385",{"type":31,"coordinates":106},[107,108],2.37681,51.0344,{"lat":108,"lon":107},[111,114],{"name":112,"role":20,"phone":10,"phoneExt":10,"email":113},"Adrien DANIEL, Dr","Adrien.daniel@ch-dunkerque.fr",{"name":112,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":116,"status":26,"city":117,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Grenoble CHU","Grenoble",{"type":31,"coordinates":119},[120,121],5.71479,45.17869,{"lat":121,"lon":120},[124],{"name":125,"role":20,"phone":10,"phoneExt":10,"email":126},"Martin Carré, Dr","MCarre1@chu-grenoble.fr",{"facility":128,"status":26,"city":129,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Le Mans CH","Le Mans",{"type":31,"coordinates":131},[132,133],0.20251,48.0021,{"lat":133,"lon":132},[136],{"name":137,"role":20,"phone":10,"phoneExt":10,"email":138},"Kamel Laribi, Dr","klaribi@ch-lemans.fr",{"facility":140,"status":26,"city":141,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Lyon sud CHU","Lyon",{"type":31,"coordinates":143},[144,145],4.84789,45.74906,{"lat":145,"lon":144},[148],{"name":149,"role":20,"phone":10,"phoneExt":10,"email":150},"Mael Heiblig, Pr","mael.heiblig@chu-lyon.fr",{"facility":152,"status":26,"city":153,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Marseille IPC","Marseille",{"type":31,"coordinates":155},[156,157],5.38107,43.29695,{"lat":157,"lon":156},[160],{"name":161,"role":20,"phone":10,"phoneExt":10,"email":162},"Sylvain GARCIAZ, Dr","GARCIAZS@ipc.unicancer.fr",{"facility":164,"status":78,"city":165,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Meaux CH de l'Est francilien","Meaux",{"type":31,"coordinates":167},[168,169],2.87885,48.96014,{"lat":169,"lon":168},[172],{"name":173,"role":20,"phone":10,"phoneExt":10,"email":174},"Jamilé Frayfer, Dr","jfrayfer@ghef.fr",{"facility":176,"status":26,"city":177,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Montpellier - Chu Saint Eloi","Montpellier",{"type":31,"coordinates":179},[180,181],3.87635,43.61093,{"lat":181,"lon":180},[184],{"name":185,"role":20,"phone":10,"phoneExt":10,"email":186},"Ludovic Gabellier, Dr","l-gabellier@chu-montpellier.fr",{"facility":188,"status":78,"city":189,"state":10,"zip":190,"country":28,"countryCode":29,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Mulhouse Chu","Mulhouse","68100",{"type":31,"coordinates":192},[193,194],7.32866,47.75205,{"lat":194,"lon":193},[197,200],{"name":198,"role":20,"phone":10,"phoneExt":10,"email":199},"Mario OJEDA-URIBE, Dr","ojeda-uribem@ghrmsa.fr",{"name":201,"role":16,"phone":10,"phoneExt":10,"email":10},"Mario ODJEDA-URIBE",{"facility":203,"status":78,"city":204,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Nantes CHU","Nantes",{"type":31,"coordinates":206},[207,208],-1.55336,47.21725,{"lat":208,"lon":207},[211],{"name":212,"role":20,"phone":10,"phoneExt":10,"email":213},"Pierre Peterlin, Dr","pierre.peterlin@chu-nantes.fr",{"facility":215,"status":26,"city":216,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Nice CHU","Nice",{"type":31,"coordinates":218},[219,220],7.26608,43.70313,{"lat":220,"lon":219},[223],{"name":224,"role":20,"phone":10,"phoneExt":10,"email":225},"Thomas Cluzeau, Prof","cluzeau.t@chu-nice.fr",{"facility":227,"status":26,"city":228,"state":10,"zip":229,"country":28,"countryCode":29,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Orléans CHU","Orléans","45000",{"type":31,"coordinates":231},[232,233],1.90407,47.90248,{"lat":233,"lon":232},[236,238],{"name":237,"role":20,"phone":10,"phoneExt":10,"email":10},"Magda ALEXIS, Dr",{"name":10,"role":20,"phone":10,"phoneExt":10,"email":239},"magda.alexis@chr-orleans.fr",{"facility":241,"status":26,"city":242,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Paris Saint Louis","Paris",{"type":31,"coordinates":244},[245,246],2.3488,48.85341,{"lat":246,"lon":245},[249],{"name":250,"role":20,"phone":10,"phoneExt":10,"email":251},"Emmanuel Raffoux, Prof","emmanuel.raffoux@aphp.fr",{"facility":253,"status":26,"city":254,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Bordeaux CHU","Pessac",{"type":31,"coordinates":256},[257,258],-0.6324,44.80565,{"lat":258,"lon":257},[261],{"name":262,"role":20,"phone":10,"phoneExt":10,"email":263},"Pierre-Yves Dumas, Prof","pierre-yves.dumas@chu-bordeaux.fr",{"facility":265,"status":26,"city":266,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":267,"geoPoint":271,"contacts":272},"ICANS - Institut de cancérologie de strasbourg europe","Strasbourg",{"type":31,"coordinates":268},[269,270],7.74553,48.58392,{"lat":270,"lon":269},[273],{"name":274,"role":20,"phone":10,"phoneExt":10,"email":275},"Celestine SIMAND, Dr","c.simand@icans.eu",{"facility":277,"status":26,"city":278,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":279,"geoPoint":283,"contacts":284},"Toulouse - IUCT Oncopole - Service d'Hématologie","Toulouse",{"type":31,"coordinates":280},[281,282],1.44367,43.60426,{"lat":282,"lon":281},[285],{"name":286,"role":20,"phone":10,"phoneExt":10,"email":287},"Sarah BERTOLI, Dr","bertoli.sarah@iuct-oncopole.fr",{"type":289,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[291],{"name":292,"class":6},"Acute Leukemia French Association","100545106","observatory-of-compassionate-use-of-ivosidenib-in-france-for-patients-with-acute-myeloid-leukemia-100545106",false,"NCT06377579","OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Patient with IDH1 R132 mutated with newly diagnosed or Relapsed or Refractory (R\u002FR) acute myeloid leukemia\n* Patient treated within French compassionate access program that have started the treatment between 01\u002F01\u002F2017 to 01\u002F08\u002F2023\n* patient treated by Ivosidenib received either as a monotherapy or in combination with other AML therapy (i.e. azacytidine, venetoclax)\n* Patient not included within IDH inhibitor clinical trial.\n\nExclusion Criteria:\n\n* Patients who expressed their opposition to entered in the study\n* Patients who received IVO through a trial","ALL","18 Years",{"count":302,"type":303},250,"ESTIMATED","6 Months","OBSERVATIONAL","Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1. Mutant IDH proteins acquire an abnormal enzymatic activity allowing them to convert α-ketoglutarate (αKG) into D-2 hydroxyglutarate (D-2HG), an oncometabolite which massively accumulates in IDH-mutated cells. At high levels, D-2HG behaves as a competitive inhibitor of αKG and affects the activity of Fe(II)\u002FαKG-dependent dioxygenases. This enzymatic family is involved in a broad spectrum of pathways such as demethylation of histone (JHDM histone demethylases) or DNA (methylcytosine hydroxylases of the TET family). As a result, IDH-mutated cells show altered survival, motility, invasiveness and cell differentiation. In AML, IDH1 mutations might be present in 10-15% at diagnosis\n\nIvosidenib (IVO) a first-in-class, oral, irreversible inhibitor of mutant IDH1 has shown clinical activity as a single agent in studies involving patients with IDH1 mutated relapsed or refractory (R\u002FR) AML and in front line settings. In phase II clinical trials, IVO yielded 30-35% of complete response rates both in frontline and R\u002FR settings, with long lasting responses. Based on these results, the FDA (Food and Drug Agency) gave its approval for newly-diagnosed AML IDH1mut patients who are ≥ 75 years old or who have comorbidities and in R\u002FR. However, European Medicines Agency (EMA)'s did not approved IVO due to lack of evidences to support the application. Agios Netherlands B.V. (the company that previously own the drug before Servier Laboratories) withdrew its EMA application. Nevertheless, IVO has been available in France through a compassionate use program (CUP), since February 2020 for R\u002FR patients and March 2022 for first line treatment.\n\nIn this multicentric retrospective study, sponsor aim to evaluate the efficacy and safety of Ivo in two cohorts of IDH1mut AML patients treated within the CUP. The first cohort will concern patients treated in first line setting and the second cohort those treated in R\u002FR disease. Results might provide new insights regarding IVO in real life settings and support signs of efficacy. This could provide new data for the haematologist community and for another appliance to grant EMA approval of IVO in the setting of R\u002FR IDH1mut AML.",[308],"AML, Adult","2025-11-25",{"date":311,"type":312},"2025-11-26","ACTUAL",{"date":314,"type":312},"2024-07-31",{"date":316,"type":303},"2026-06-01",{"name":5,"class":6},21]